

Anders Fogelberg appointed as Chief Commercial Officer for BICO Group AB (publ)

BICO Group AB today announces the appointment of Anders Fogelberg as Chief Commercial Officer (CCO). Commercial excellence has been defined as one of the top strategic priorities for BICO and this position is pivotal in setting and driving the strategy towards that target, i.e., in scaling the BICO business, increasing the commercialization efforts of the portfolio and further explore opportunities for collaborations and partnerships.

Anders Fogelberg has 20+ years' experience of working with marketing and sales & business development in global organizations. He has extensive experience from different leadership positions foremost as a Managing Director for the SKF Group in Malaysia and Indonesia respectively. Before joining BICO, Anders has worked in the Med Tech industry now latest as Chief Marketing Officer and Head of Sales for Profundus and before that as CEO for Bellman & Symfon.

"Anders extensive global industry experience with a strong track record of commercial success including turnarounds and pharma collaborations will be a great addition to our team on our journey of improving the commercial excellence." says Maria Forss, CEO and President BICO Group AB.

"I'm excited to join the BICO team and work with an organization that has produced so many innovative life science solutions and contribute to the continuing transformation and growth of the company." says Anders Fogelberg, assuming CCO, BICO Group AB.

Anders Fogelberg will assume his new position on June 13, 2024. The CCO role is newly established, will be a member of the Executive Management and report to BICO's CEO and President. The CCO will be main responsible for the commercial activities within the BICO Group and ensure cooperation between subsidiaries and that long-term partnerships are built with relevant partners throughout the global life science industry.

BICO's Executive Management has transformed significantly since the beginning of 2023 with appointments of new CEO, CFO, COO, and CHRO (Chief Human Resources Officer). This has formed a new leadership at BICO.

For further information, please contact:

Maria Forss, President & CEO, BICO Group AB

Phone: EA Isabella Lundin +46 73 515 99 64

E-mail: mf@bico.com

The information was submitted for publication, through the agency of the contact person set out above, on April 18, 2024 at 07.00am CEST.

About BICO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 46,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 12,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world's organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments

[Anders Fogelberg appointed as Chief Commercial Officer for BICO Group AB \(publ\)](#)